{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:43:40Z","timestamp":1782470620704,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40120-025-00711-3","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T22:15:45Z","timestamp":1739830545000},"page":"575-591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Risk of Exacerbation and Level of Healthcare Resource Utilization in Myasthenia Gravis Assessed by Myasthenia Gravis Activities of Daily Living Score"],"prefix":"10.1007","volume":"14","author":[{"given":"Angela","family":"Ting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oshin","family":"Sangha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"711_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5:30.","journal-title":"Nat Rev Dis Primers"},{"key":"711_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-2-44","volume":"2","author":"VC Juel","year":"2007","unstructured":"Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44.","journal-title":"Orphanet J Rare Dis"},{"key":"711_CR3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. J Neurol. 2016;263:1473\u201394.","journal-title":"J Neurol"},{"key":"711_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87:419\u201325.","journal-title":"Neurology"},{"key":"711_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/mus.27791","volume":"67","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A. Treatment patterns in myasthenia gravis: a United States health claims analysis. Muscle Nerve. 2023;67:297\u2013305.","journal-title":"Muscle Nerve"},{"key":"711_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","volume":"60","author":"G Cutter","year":"2019","unstructured":"Cutter G, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60:707\u201315.","journal-title":"Muscle Nerve"},{"key":"711_CR7","doi-asserted-by":"crossref","unstructured":"Pisc J, Ting A, Skornicki M, Sinno O, Lee E. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the US: a retrospective analysis of claims data. J Comp Eff Res. 2024;13:e230108.","DOI":"10.57264\/cer-2023-0108"},{"key":"711_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120531","volume":"445","author":"A Ting","year":"2023","unstructured":"Ting A, Story T, Lecomte C, Estrin A, Syed S, Lee E. A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment. J Neurol Sci. 2023;445:120531.","journal-title":"J Neurol Sci"},{"key":"711_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Neurol. 2023;22:395\u2013406.","journal-title":"Lancet Neurol"},{"key":"711_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive Phase 3 study. Lancet Neurol. 2023;22:383\u201394.","journal-title":"Lancet Neurol"},{"key":"711_CR11","doi-asserted-by":"crossref","unstructured":"Vu T, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1:EVIDoa2100066.","DOI":"10.1056\/EVIDoa2100066"},{"key":"711_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet Neurol. 2021;20:526\u201336.","journal-title":"Lancet Neurol"},{"key":"711_CR13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52:1487\u20139.","journal-title":"Neurology"},{"key":"711_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve. 2022;65:630\u20139.","journal-title":"Muscle Nerve"},{"key":"711_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mus.26104","volume":"58","author":"I Lee","year":"2018","unstructured":"Lee I, Kaminski HJ, Xin H, Cutter G. Gender and quality of life in myasthenia gravis patients from the Myasthenia Gravis Foundation of America registry. Muscle Nerve. 2018;58:90\u20138.","journal-title":"Muscle Nerve"},{"key":"711_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mus.26694","volume":"60","author":"L Harris","year":"2019","unstructured":"Harris L, Aban IB, Xin H, Cutter G. Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America Registry analysis. Muscle Nerve. 2019;60:700\u20136.","journal-title":"Muscle Nerve"},{"key":"711_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/CND.0000000000000301","volume":"22","author":"L Harris","year":"2020","unstructured":"Harris L, Allman PH, Sheffield R, Cutter G. Longitudinal analysis of disease burden in refractory and nonrefractory generalized myasthenia gravis in the United States. J Clin Neuromuscul Dis. 2020;22:11\u201321.","journal-title":"J Clin Neuromuscul Dis"},{"key":"711_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.27659","volume":"66","author":"I Lee","year":"2022","unstructured":"Lee I, Leach JM, Aban I, McPherson T, Duda PW, Cutter G. One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: from the MG Patient Registry. Muscle Nerve. 2022;66:411\u201320.","journal-title":"Muscle Nerve"},{"key":"711_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CND.0000000000000257","volume":"20","author":"AN Boscoe","year":"2019","unstructured":"Boscoe AN, Xin H, L\u2019Italien GJ, Harris LA, Cutter GR. Impact of refractory myasthenia gravis on health-related quality of life. J Clin Neuromuscul Dis. 2019;20:173\u201381.","journal-title":"J Clin Neuromuscul Dis"},{"key":"711_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000524733","volume":"56","author":"MJ Syed","year":"2022","unstructured":"Syed MJ, Khawaja A, Lisak RP. Are there racial differences in inpatient outcomes and treatment utilization following hospitalization for myasthenia gravis exacerbation? Neuroepidemiology. 2022;56:380\u20138.","journal-title":"Neuroepidemiology"},{"key":"711_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506310","volume":"54","author":"E Guastafierro","year":"2020","unstructured":"Guastafierro E, et al. Employment in myasthenia gravis: a systematic literature review and meta-analysis. Neuroepidemiology. 2020;54:304\u201312.","journal-title":"Neuroepidemiology"},{"key":"711_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013278","volume":"7","author":"Y Nagane","year":"2017","unstructured":"Nagane Y, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7: e013278.","journal-title":"BMJ Open"},{"key":"711_CR23","unstructured":"US Bureau of Labor Statistics. Civilian unemployment rate. https:\/\/www.bls.gov\/charts\/employment-situation\/civilian-unemployment-rate.htm. Accessed Apr 2024."},{"key":"711_CR24","unstructured":"Thompson J, Zhang B, Liberman JN, Darer J. Social determinants of health are associated with suboptimal treatment among individuals with myasthenia gravis. Poster 23 in MGFA Scientific Session at: AANEM; 2023 Nov 1\u20134; Phoenix, AZ, USA."},{"key":"711_CR25","doi-asserted-by":"publisher","first-page":"1147489","DOI":"10.3389\/fpubh.2023.1147489","volume":"11","author":"T Hughes","year":"2023","unstructured":"Hughes T, et al. Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs. Front Public Health. 2023;11:1147489.","journal-title":"Front Public Health"},{"key":"711_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07368-0","author":"V Di Stefano","year":"2024","unstructured":"Di Stefano V, et al. Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients. Neurol Sci. 2024. https:\/\/doi.org\/10.1007\/s10072-024-07368-0. (Epub ahead of print).","journal-title":"Neurol Sci"},{"key":"711_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/brainsci13020170","volume":"13","author":"S Iacono","year":"2023","unstructured":"Iacono S, et al. Frequency and correlates of mild cognitive impairment in myasthenia gravis. Brain Sci. 2023;13:170.","journal-title":"Brain Sci"},{"key":"711_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126579","volume":"10","author":"S Konno","year":"2015","unstructured":"Konno S, et al. Association between glucocorticoid-induced osteoporosis and myasthenia gravis: a cross-sectional study. PLoS ONE. 2015;10: e0126579.","journal-title":"PLoS ONE"},{"key":"711_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","volume":"18","author":"JX Li","year":"2022","unstructured":"Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol. 2022;18:540\u201357.","journal-title":"Nat Rev Endocrinol"},{"key":"711_CR30","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/jcm10071537","volume":"10","author":"S Sheikh","year":"2021","unstructured":"Sheikh S, Alvi U, Soliven B, Rezania K. Drugs that induce or cause deterioration of myasthenia gravis: an update. J Clin Med. 2021;10:1537.","journal-title":"J Clin Med"},{"key":"711_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12955-020-01549-z","volume":"18","author":"D Dong","year":"2020","unstructured":"Dong D, et al. Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes. 2020;18:296.","journal-title":"Health Qual Life Outcomes"},{"key":"711_CR32","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/mus.27331","volume":"64","author":"JLS Thomsen","year":"2021","unstructured":"Thomsen JLS, Vinge L, Harbo T, Andersen H. Gender differences in clinical outcomes in myasthenia gravis: a prospective cohort study. Muscle Nerve. 2021;64:538\u201344.","journal-title":"Muscle Nerve"},{"key":"711_CR33","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/genes13040696","volume":"13","author":"V Nicoli","year":"2022","unstructured":"Nicoli V, et al. Preferential X chromosome inactivation as a mechanism to explain female preponderance in myasthenia gravis. Genes. 2022;13:696.","journal-title":"Genes"},{"key":"711_CR34","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1212\/WNL.0000000000003339","volume":"87","author":"MI Boldingh","year":"2016","unstructured":"Boldingh MI, Maniaol AH, Brunborg C, Weedon-Fekj\u00e6r H, Verschuuren JJ, Tallaksen CM. Increased risk for clinical onset of myasthenia gravis during the postpartum period. Neurology. 2016;87:2139\u201345.","journal-title":"Neurology"},{"key":"711_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0022-510X(98)00031-8","volume":"156","author":"RR Leker","year":"1998","unstructured":"Leker RR, Karni A, Abramsky O. Exacerbation of myasthenia gravis during the menstrual period. J Neurol Sci. 1998;156:107\u201311.","journal-title":"J Neurol Sci"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00711-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00711-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00711-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:31:16Z","timestamp":1741851076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00711-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00711-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Angela Ting is a former employee and shareholder of UCB. Mohita Kumar and Edward Lee are employees and shareholders of UCB. Minjee Park and Jean-Fran\u00e7ois Ricci are employees of Alira Health. Oshin Sangha is a former employee of Alira Health and a member of the MGFA Registry Advisory Council. Richard J. Nowak reports research support from Alexion Pharmaceuticals, argenx, Annexon Biosciences, Genentech, Grifols, Immunovant, Momenta (now Johnson & Johnson), the MGFA, the National Institutes of Health, UCB, and Horizon Therapeutics (now Amgen). Richard J. Nowak has also served as a consultant and advisor for Alexion Pharmaceuticals, argenx, Cabaletta Bio, COUR Pharmaceuticals, CSL Behring, Grifols, Immunovant, Momenta (now Johnson & Johnson), UCB, and Horizon Therapeutics (now Amgen).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"MGFAPR is a patient-driven registry funded and supervised by the MGFA and managed by Alira Health since June 2022. The MGFAPR is approved by the WCG Institutional Review Board (IRB tracking number: 20223601), and the database is Health Insurance Portability and Accountability Act compliant. This study followed the 2005 Guidelines for Good Pharmacoepidemiological Practice (GPP) and the 2015 International Society of Pharmacoepidemiology Guidelines for GPP. All patients provided informed, voluntary consent to enroll in the MGFAPR and for their data to be used in research studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}